Avanir‘s investigational drug Zenvia met its primary efficacy endpoint in the treatment of pseudobulbar affect (PBA) in a confirmatory Phase III trial. Both Zenvia 30/10 mg and 20/10 mg provided a statistically significant reduction in episode rates over the course of the study when compared to placebo (p<0.0001). In an additional analysis of the primary endpoint, at week 12 (end of study), patients in the 30/10 mg group reported a statistically significant mean reduction of 88% from ba...